▎ 摘　　要

NOVELTY - Graphene-based drug carrier comprises mesoporous silica-surface modified polydopamine-coated reduced graphene oxide. The thickness of mesoporous silica layer is 2-50 nm. The thickness of polydopamine layer is 1-30 nm. USE - Graphene-based drug carrier used for preparing photothermal therapeutic agent (claimed). ADVANTAGE - The carrier has enhanced biocompatibility and increased photothermal absorption performance. DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for preparation of graphene-based drug carrier comprising dispersing graphene oxide in pH 8-9 buffer solution, adding dopamine hydrochloride, heating at 50-90 degrees C for 4-48 hours to obtain polydopamine-coated reduced graphene oxide, dispersing polydopamine-coated reduced graphene oxide in aqueous solution, adding cationic surfactant, adjusting pH of mixture to 10-12, adding organosilane, and reacting at room temperature for 12-36 hours to obtain drug carrier.